USPTO Grants Patent for Glutathione Trisulfide in Neuroprotection

The United States Patent and Trademark Office (USPTO) has granted patent US12582693B2 for methods involving the use of glutathione trisulfide (GSSSG) in neuroprotection. The patent, assigned to The General Hospital Corporation, specifically details applications for treating neurodegenerative diseases and mitigating the risk of ischemic injury to the brain, spinal cord, and peripheral nerves. The invention pertains to conditions that compromise blood flow and oxygen delivery, such as those resulting from surgery or trauma.

This patent grant signifies a new intellectual property right for a specific therapeutic method. While not a regulatory rule imposing obligations on other entities, it establishes exclusive rights for the assignee. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in neurological treatments or therapies for stroke and trauma, should be aware of this granted patent to avoid potential infringement. No immediate compliance actions are required for external parties, but it impacts the competitive landscape for developing similar treatments.